|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis.
|
29416352 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients.
|
27780361 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Vascular endothelial growth factor serum levels were analyzed in patients with EOC.
|
28574932 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In our large multi-center study, the investigated VEGF gene polymorphisms were not associated with prognosis in patients with ovarian cancer.
|
17289129 |
2007 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we demonstrated that the upregulation of SP1 enhanced expression of VEGF promoting the angiogenesis and migration of trastuzumab-resistant ovarian cancer cell line SKOV3-T. Our in vitro and in vivo results both gave evidence that the SP1-VEGF axis was responsible for the enhanced malignancy, angiogenesis and migration in the acquired trastuzumab-resistant ovarian cancer cell model.
|
29048687 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, to examine whether NGF and VEGF secreted by epithelial ovarian cancer (EOC) explants and from epithelial ovarian cancer cell line (A2780) are involved in the process of angiogenesis, such as cellular proliferation, migration and differentiation of the human endothelial cell line (EA.hy926).
|
21236475 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF concentrations in ascites significantly increased in c-MYC-induced ovarian cancer, whereas the concentrations of inflammatory cytokines in ascites were significantly high in KRAS-induced ovarian cancer and were accompanied by an increased number of neutrophils in ascites.
|
27483433 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.
|
12466143 |
2002 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF mean rank was significantly higher in ovarian cancer tumors compared to benign lesions (P < 0.001).
|
15087251 |
2004 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment.
|
25637316 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In epithelial ovarian cancer (EOC) cells, ET-1/ET(A)R axis induced vascular-endothelial growth factor (VEGF) expression through HIF-1α nuclear accumulation.
|
26909598 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oxytocin inhibits ovarian cancer metastasis by repressing the expression of MMP-2 and VEGF.
|
29721047 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data present, for the first time, preliminary evidence that VEGF C936T alone or combined with the COL18A1 D104N polymorphism of AG constitutes an important inherited EOC determinant.
|
25092217 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heparanase (HSPE-1) and vascular endothelial growth factor (VEGF), proangiogenic growth factors, play important roles in the metastatic biology of ovarian cancer.
|
17419711 |
2007 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) is a prognostic factor and target treatment for metastatic colorectal and ovarian cancer.
|
24075030 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
VEGF gene expression was analyzed by real-time quantitative reverse transcription-polymerase chain reaction in 178 surgical epithelial ovarian cancer specimens.
|
21378364 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent evidence suggests that proangiogenic factors other than the widely known, potent angiogenic factor vascular endothelial growth factor may mediate growth and metastasis of ovarian cancer.
|
26610586 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to investigate the effects of silencing HIF-1 alpha gene expression with specific small interfering RNA (siRNA) on VEGF production and angiogenesis in epithelial ovarian cancer (EOC) cells.
|
20140681 |
2010 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AEG-1, HIF-1<i>α</i>, and VEGF amounts were significantly elevated in EOC tissue samples compared with normal ovary specimens (<i>p</i> < 0.001).
|
29770329 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
|
21041183 |
2010 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGF‑R2 in patients with ovarian cancer at FIGO stages I-II.
|
30066848 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cediranib potently and selectively inhibits all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), and clinical studies have shown that it is effective in patients with ovarian cancer at a dose of 20 mg/day.
|
27943222 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
G. lucidum inhibits ovarian cancer by down-regulating the expression of VEGF and up-regulating the downstream Cx43 expression.
|
25374251 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since telomerase, a ribonucleprotein expressed in 95% of ovarian cancers, plays an important role in cellular immortalization, growth, and tumor progression, we examined whether telomerase is a molecular target of LPA and VEGF in ovarian cancer.
|
17559911 |
2007 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that the PI3K/Akt-Sp1 pathway is involved in resistin-induced VEGF expression in HO-8910 cells and indicates that antiangiogenesis therapy may be beneficial treatment against ovarian epithelial carcinoma, especially in obese patients.
|
23652833 |
2013 |